中国基层医药
中國基層醫藥
중국기층의약
CHINESE JOURNAL OF PRIMARY MEDICINE AND PHARMACY
2012年
13期
1933-1934
,共2页
高宗毅%贾立娟%刘永利%刘江涛%贾彦丽
高宗毅%賈立娟%劉永利%劉江濤%賈彥麗
고종의%가립연%류영리%류강도%가언려
癌,非小细胞肺%放射疗法,适形
癌,非小細胞肺%放射療法,適形
암,비소세포폐%방사요법,괄형
Carcinoma,non-small-cell lung%Radiotherapy,conformal
目的 探讨三维适形放射不同剂量分割治疗晚期非小细胞肺癌( NSCLC)的近期疗效.方法 148例NSCLC随机采用三维适形放疗(3DCRT)(观察组,75例)和常规分割照射治疗(对照组,73例),观察近期疗效和不良反应,随访患者治疗后1、2、3年生存情况.结果 对照组总有效47例(64.4%),观察组总有效60例(80.0%),两组差异有统计学意义(x2=4.50,P<0.05).对照组1、2、3年生存率为50.7%、24.7%、8.2%,中位生存期为13个月;观察组分别为73.3%、45.3%、20.0%,中位生存期为19个月.两组生存率差异有统计学意义(x2=8.07、6,94、4.22,均P<0.05).观察组血液系统副反应发生率明显低于对照组(x2=4.73,P<0.05),两组急性放射性肺炎、放射性食管炎发生率差异无统计学意义(P>0.05).结论 3 DC RT对晚期NSCLC近期疗效好,且治疗不良反应低,值得在临床上推广应用.
目的 探討三維適形放射不同劑量分割治療晚期非小細胞肺癌( NSCLC)的近期療效.方法 148例NSCLC隨機採用三維適形放療(3DCRT)(觀察組,75例)和常規分割照射治療(對照組,73例),觀察近期療效和不良反應,隨訪患者治療後1、2、3年生存情況.結果 對照組總有效47例(64.4%),觀察組總有效60例(80.0%),兩組差異有統計學意義(x2=4.50,P<0.05).對照組1、2、3年生存率為50.7%、24.7%、8.2%,中位生存期為13箇月;觀察組分彆為73.3%、45.3%、20.0%,中位生存期為19箇月.兩組生存率差異有統計學意義(x2=8.07、6,94、4.22,均P<0.05).觀察組血液繫統副反應髮生率明顯低于對照組(x2=4.73,P<0.05),兩組急性放射性肺炎、放射性食管炎髮生率差異無統計學意義(P>0.05).結論 3 DC RT對晚期NSCLC近期療效好,且治療不良反應低,值得在臨床上推廣應用.
목적 탐토삼유괄형방사불동제량분할치료만기비소세포폐암( NSCLC)적근기료효.방법 148례NSCLC수궤채용삼유괄형방료(3DCRT)(관찰조,75례)화상규분할조사치료(대조조,73례),관찰근기료효화불량반응,수방환자치료후1、2、3년생존정황.결과 대조조총유효47례(64.4%),관찰조총유효60례(80.0%),량조차이유통계학의의(x2=4.50,P<0.05).대조조1、2、3년생존솔위50.7%、24.7%、8.2%,중위생존기위13개월;관찰조분별위73.3%、45.3%、20.0%,중위생존기위19개월.량조생존솔차이유통계학의의(x2=8.07、6,94、4.22,균P<0.05).관찰조혈액계통부반응발생솔명현저우대조조(x2=4.73,P<0.05),량조급성방사성폐염、방사성식관염발생솔차이무통계학의의(P>0.05).결론 3 DC RT대만기NSCLC근기료효호,차치료불량반응저,치득재림상상추엄응용.
Objective To explore the effect of three-dimensional conformal radiation dose fractionation treatment of advanced non-small cell lung cancer(NSCLC).Methods 75 NSCLC patients were treated with hypofractionated 3DCRT( observation group),while 73 cases were treated with conventional fractionated radiotherapy (control group).The efficacy and adverse reactions were observed;Survival after treatment were followed up in 1,2,3 years.Lung function was detected before and after radiotherapy treatment,including FVC,FEV1 and CLCO.Results The total effective cases of control group were 47 cases patients ( 64.4% ),observation group's was 60 cases ( 80.0% ),total effective rate had statistically significant difference ( x2 =4.50,P < 0.05 ).Survival of control group after treatment in 1,2,3year were 50.7%,24.7%,8.2%,the median survival was 13 months,observation group's were 73.3%,45.3%,20.0%,and 19 months.The survival of these two groups was statistically different (x2 =8.07,6,94,4.22,all P < 0.05 ).The patients blood system side effects of observation group were significantly lower than the control group ( x2 =4.73,P <0.05 ) ;acute radiation pneumonia,esophagitis of these two groups had no significant difference in the incidence( P > 0.05 ).Conclusion Hypofractionated 3DCRT treatment of advanced NSCLC had good effect,and its adverse reactions was low,and it was worthy of clinical application.